查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1423777

帶狀皰疹後神經痛治療的全球市場 - 全球產業分析、規模、份額、成長、趨勢、預測 (2031) - 按治療類型、按分銷管道、按地區

Post Herpetic Neuralgia Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region:
出版日期: | 出版商: Fairfield Market Research | 英文 214 Pages | 商品交期: 2-5個工作天內

價格
簡介目錄

帶狀皰疹後神經痛 (PHN) 的特徵是由於水痘帶狀皰疹病毒（帶狀皰疹）重新激活導致周圍神經損傷而引起的中度至重度神經痛。 PHN 是帶狀皰疹重新活化後持續超過 30 天的神經痛。 全球帶狀皰疹後神經痛治療市場主要由輝瑞公司、梯瓦製藥工業有限公司、Mylan N.V.和Endo Pharmaceuticals Inc.等主要製造商推動，這些製造商合計佔市場收入的50%。 這些領先的製造商正在利用人們對帶狀皰疹後神經痛治療的認識不斷增強以及老年人口不斷增長的趨勢。

雖然帶狀皰疹後神經痛治療市場由大型供應商主導，但由於專利到期以及與治療方案相關的功效和效率挑戰，整合並不一定會轉化為盈利能力的增加。 然而，隨著帶狀皰疹後神經痛治療意識的增強，市場動態正在發生變化，尤其是在老年人中。

由於帶狀皰疹後神經痛盛行率上升和老年人口不斷擴大，全球帶狀皰疹後神經痛治療市場正在成長。 此外，全球醫療保健基礎設施的改善和政府對帶狀皰疹後神經痛治療產品的支持預計將推動市場成長。

帶狀皰疹後神經痛治療市場的關鍵驅動因素是篩檢率的提高和老年人口的增加。 根據疾病管制與預防中心的數據，美國成年人的帶狀皰疹發病率呈上升趨勢，大約三分之一的人在一生中患有帶狀皰疹。 大部分帶狀皰疹病例會導致帶狀皰疹後神經痛，尤其是 50 歲以上的人。

儘管市場潛力巨大，但對阿片類藥物使用和用藥過量死亡率上升的擔憂是帶狀皰疹後神經痛治療市場的主要限制因素。 阿片類藥物過量死亡佔藥物過量死亡的很大一部分，引起了人們對治療選擇的擔憂。

本報告考察了全球帶狀皰疹後神經痛治療市場，並提供了市場概況，包括按治療類型、分銷渠道、地區劃分的趨勢以及進入市場的公司的競爭趨勢。Masu。

目錄

第 1 章執行摘要

第2章市場概述

  • 市場定義與細分
  • 市場動態
  • 價值鏈分析
  • 波特五力分析
  • 新冠肺炎 (COVID-19) 影響分析
  • 烏克蘭和俄羅斯之間衝突的影響
  • 經濟概況
  • 杵分析

第3章2018-2031年全球帶狀皰疹後神經痛治療市場展望

  • 2018-2031 年全球帶狀皰疹後神經痛治療市場展望（按治療類型、價值（十億美元））
  • 2018-2031 年全球帶狀皰疹後神經痛治療市場展望，按分銷管道劃分，價值（十億美元）
  • 2018-2031 年全球帶狀皰疹後神經痛治療市場展望（按地區、價值（十億美元））

第4章2018-2031年北美帶狀皰疹後神經痛治療市場前景

第5章歐洲帶狀皰疹後神經痛治療市場前景，2018-2031

第6章亞太地區帶狀皰疹後神經痛治療市場展望，2018-2031

第 7 章拉丁美洲帶狀皰疹後神經痛治療市場展望，2018-2031

第8章中東與非洲帶狀皰疹後神經痛治療市場前景，2018-2031

第9章競爭態勢

  • 治療類型和分銷管道的熱圖
  • 製造商和分銷通路熱圖
  • 2023 年公司市佔率分析
  • 競爭對手儀表板
  • 公司簡介
    • Pfizer Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Mylan N.V.
    • Endo Pharmaceuticals Inc.
    • Daiichi Sankyo
    • Acorda Therapeutics
    • Purdue Pharma L.P
    • Teikoku Pharma USA, Inc.
    • Janssen Pharmaceuticals, Inc.

第10章 附錄

簡介目錄

Post herpetic neuralgia (PHN) is characterized by moderate to severe nerve pain resulting from damage to a peripheral nerve due to the reactivation of the varicella zoster virus (shingles). PHN is nerve pain that persists for more than 30 days after the reactivation of herpes zoster.The global post herpetic neuralgia treatment market is predominantly driven by key players, including Pfizer Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., and Endo Pharmaceuticals Inc., who collectively account for more than 50% of the market's revenue. These leading manufacturers are capitalizing on growing awareness about post herpetic neuralgia treatment and the increasing geriatric population.

Market Consolidation and Challenges

While large vendors dominate the post herpetic neuralgia treatment market, consolidation hasn't necessarily translated into increased profitability due to patent expirations and the effectiveness and efficiency challenges associated with treatment options. However, the market's dynamics are evolving as awareness about post herpetic neuralgia treatment grows, especially among the elderly.

Drivers of Market Growth

The global post herpetic neuralgia treatment market is experiencing growth due to the rising prevalence of post herpetic neuralgia and the expanding geriatric population. Furthermore, the development of healthcare infrastructure globally, coupled with government support for post herpetic neuralgia treatment products, is expected to drive market growth.

Growing Geriatric Population and Screening Rates

The increasing rates of screening and the growth in the geriatric population are critical drivers of the post herpetic neuralgia treatment market. According to the Center for Disease Control and Prevention, shingles is on the rise among adults in the United States, with approximately 1 in 3 people developing shingles in their lifetime. A significant percentage of shingles cases result in post herpetic neuralgia, particularly in individuals aged 50 and older.

Concerns Over Opioid Use

Despite the market's potential, concerns over opioid use and the rising mortality rates due to overdoses pose significant constraints on the post herpetic neuralgia treatment market. Opioid overdose deaths, accounting for a substantial portion of drug overdose fatalities, have raised concerns over treatment options.

Opportunities in New Drug Development

The development of new drugs presents a significant opportunity in the post herpetic neuralgia treatment market, as a definitive curative treatment is yet to be discovered. Government support for post herpetic neuralgia treatment products, particularly through initiatives and investments in research and development, is expected to foster market growth.

Regional Variations in Market Growth

In developed regions like North America and Europe, the presence of a larger economy, higher purchasing power, and extensive healthcare infrastructure support the growth of the post herpetic neuralgia treatment market. The U.S., in particular, stands out due to excellent reimbursement policies and increasing incidence rates of post herpetic neuralgia. In Asia Pacific, Japan, India, Australia, and New Zealand are key players in the market.

Challenges to Market Realization

Despite the market's potential, challenges remain, particularly related to the efficacy and efficiency of treatment options. While calcium-channel blockers, tricyclic antidepressants, steroids, and opioids are used in post herpetic neuralgia treatment, they have limitations and side effects that restrict their widespread use.

Competitive Analysis

The post herpetic neuralgia treatment market features key players such as Pfizer Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Endo Pharmaceuticals Inc., and others. These players are profiled in the competition section of the report, outlining their market shares, strategies, product offerings, marketing approaches, and company dashboards.

Post Herpetic Neuralgia Treatment Market Segmentation:

The report presents a detailed segmentation of the post-herpetic neuralgia treatment market based on treatment type, distribution channels, and region. The treatment types include drugs, patches, and steroid injectables. Within the drug segment, further subdivisions are made for anticonvulsants, antidepressants, and opioids.

Under the patches segment, there are subdivisions for lidocaine skin patches and capsaicin skin patches. Distribution channels comprise institutional sales, which encompass hospital pharmacies and clinics, and retail sales, which include retail pharmacies, drug stores, and mail-order pharmacies.

The post-herpetic neuralgia treatment market analysis covers regions including North America, Latin America, Europe, Asia Pacific excluding China, China, and the Middle East and Africa.

Table of Contents

1. Executive Summary

  • 1.1. Global Post Herpetic Neuralgia Treatment Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2023
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. Porter's Five Forces Analysis
  • 2.5. COVID-19 Impact Analysis
    • 2.5.1. Supply
    • 2.5.2. Demand
  • 2.6. Impact of Ukraine-Russia Conflict
  • 2.7. Economic Overview
    • 2.7.1. World Economic Projections
  • 2.8. PESTLE Analysis

3. Global Post Herpetic Neuralgia Treatment Market Outlook, 2018 - 2031

  • 3.1. Global Post Herpetic Neuralgia Treatment Market Outlook, by Treatment Type, Value (US$ Bn), 2018 - 2031
    • 3.1.1. Key Highlights
      • 3.1.1.1. Drugs
        • 3.1.1.1.1. Anticonvulsants
        • 3.1.1.1.2. Antidepressants
        • 3.1.1.1.3. Opioids
      • 3.1.1.2. Patches
        • 3.1.1.2.1. Lidocaine Patches
        • 3.1.1.2.2. Capsaicin Patches
      • 3.1.1.3. Steroid Injectable
  • 3.2. Global Post Herpetic Neuralgia Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 3.2.1. Key Highlights
      • 3.2.1.1. Institutional Sales
        • 3.2.1.1.1. Hospital Pharmacies
        • 3.2.1.1.2. Clinics
      • 3.2.1.2. Retail Sales
        • 3.2.1.2.1. Retail Pharmacies
        • 3.2.1.2.2. Drug Stores
        • 3.2.1.2.3. Mail Order Pharmacies
  • 3.3. Global Post Herpetic Neuralgia Treatment Market Outlook, by Region, Value (US$ Bn), 2018 - 2031
    • 3.3.1. Key Highlights
      • 3.3.1.1. North America
      • 3.3.1.2. Europe
      • 3.3.1.3. Asia Pacific
      • 3.3.1.4. Latin America
      • 3.3.1.5. Middle East & Africa

4. North America Post Herpetic Neuralgia Treatment Market Outlook, 2018 - 2031

  • 4.1. North America Post Herpetic Neuralgia Treatment Market Outlook, by Treatment Type, Value (US$ Bn), 2018 - 2031
    • 4.1.1. Key Highlights
      • 4.1.1.1. Drugs
        • 4.1.1.1.1. Anticonvulsants
        • 4.1.1.1.2. Antidepressants
        • 4.1.1.1.3. Opioids
      • 4.1.1.2. Patches
        • 4.1.1.2.1. Lidocaine Patches
        • 4.1.1.2.2. Capsaicin Patches
      • 4.1.1.3. Steroid Injectable
  • 4.2. North America Post Herpetic Neuralgia Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 4.2.1. Key Highlights
      • 4.2.1.1. Institutional Sales
        • 4.2.1.1.1. Hospital Pharmacies
        • 4.2.1.1.2. Clinics
      • 4.2.1.2. Retail Sales
        • 4.2.1.2.1. Retail Pharmacies
        • 4.2.1.2.2. Drug Stores
        • 4.2.1.2.3. Mail Order Pharmacies
  • 4.3. North America Post Herpetic Neuralgia Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 4.3.1. Key Highlights
      • 4.3.1.1. U.S. Post Herpetic Neuralgia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
      • 4.3.1.2. U.S. Post Herpetic Neuralgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 4.3.1.3. Canada Post Herpetic Neuralgia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
      • 4.3.1.4. Canada Post Herpetic Neuralgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 4.3.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Post Herpetic Neuralgia Treatment Market Outlook, 2018 - 2031

  • 5.1. Europe Post Herpetic Neuralgia Treatment Market Outlook, by Treatment Type, Value (US$ Bn), 2018 - 2031
    • 5.1.1. Key Highlights
      • 5.1.1.1. Drugs
        • 5.1.1.1.1. Anticonvulsants
        • 5.1.1.1.2. Antidepressants
        • 5.1.1.1.3. Opioids
      • 5.1.1.2. Patches
        • 5.1.1.2.1. Lidocaine Patches
        • 5.1.1.2.2. Capsaicin Patches
      • 5.1.1.3. Steroid Injectable
  • 5.2. Europe Post Herpetic Neuralgia Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 5.2.1. Key Highlights
      • 5.2.1.1. Institutional Sales
        • 5.2.1.1.1. Hospital Pharmacies
        • 5.2.1.1.2. Clinics
      • 5.2.1.2. Retail Sales
        • 5.2.1.2.1. Retail Pharmacies
        • 5.2.1.2.2. Drug Stores
        • 5.2.1.2.3. Mail Order Pharmacies
  • 5.3. Europe Post Herpetic Neuralgia Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 5.3.1. Key Highlights
      • 5.3.1.1. Germany Post Herpetic Neuralgia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
      • 5.3.1.2. Germany Post Herpetic Neuralgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.3.1.3. U.K. Post Herpetic Neuralgia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
      • 5.3.1.4. U.K. Post Herpetic Neuralgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.3.1.5. France Post Herpetic Neuralgia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
      • 5.3.1.6. France Post Herpetic Neuralgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.3.1.7. Italy Post Herpetic Neuralgia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
      • 5.3.1.8. Italy Post Herpetic Neuralgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.3.1.9. Turkey Post Herpetic Neuralgia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
      • 5.3.1.10. Turkey Post Herpetic Neuralgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.3.1.11. Russia Post Herpetic Neuralgia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
      • 5.3.1.12. Russia Post Herpetic Neuralgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.3.1.13. Rest of Europe Post Herpetic Neuralgia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
      • 5.3.1.14. Rest of Europe Post Herpetic Neuralgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 5.3.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Post Herpetic Neuralgia Treatment Market Outlook, 2018 - 2031

  • 6.1. Asia Pacific Post Herpetic Neuralgia Treatment Market Outlook, by Treatment Type, Value (US$ Bn), 2018 - 2031
    • 6.1.1. Key Highlights
      • 6.1.1.1. Drugs
        • 6.1.1.1.1. Anticonvulsants
        • 6.1.1.1.2. Antidepressants
        • 6.1.1.1.3. Opioids
      • 6.1.1.2. Patches
        • 6.1.1.2.1. Lidocaine Patches
        • 6.1.1.2.2. Capsaicin Patches
      • 6.1.1.3. Steroid Injectable
  • 6.2. Asia Pacific Post Herpetic Neuralgia Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 6.2.1. Key Highlights
      • 6.2.1.1. Institutional Sales
        • 6.2.1.1.1. Hospital Pharmacies
        • 6.2.1.1.2. Clinics
      • 6.2.1.2. Retail Sales
        • 6.2.1.2.1. Retail Pharmacies
        • 6.2.1.2.2. Drug Stores
        • 6.2.1.2.3. Mail Order Pharmacies
  • 6.3. Asia Pacific Post Herpetic Neuralgia Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 6.3.1. Key Highlights
      • 6.3.1.1. China Post Herpetic Neuralgia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
      • 6.3.1.2. China Post Herpetic Neuralgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 6.3.1.3. Japan Post Herpetic Neuralgia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
      • 6.3.1.4. Japan Post Herpetic Neuralgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 6.3.1.5. South Korea Post Herpetic Neuralgia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
      • 6.3.1.6. South Korea Post Herpetic Neuralgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 6.3.1.7. India Post Herpetic Neuralgia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
      • 6.3.1.8. India Post Herpetic Neuralgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 6.3.1.9. Southeast Asia Post Herpetic Neuralgia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
      • 6.3.1.10. Southeast Asia Post Herpetic Neuralgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 6.3.1.11. Rest of Asia Pacific Post Herpetic Neuralgia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
      • 6.3.1.12. Rest of Asia Pacific Post Herpetic Neuralgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 6.3.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Post Herpetic Neuralgia Treatment Market Outlook, 2018 - 2031

  • 7.1. Latin America Post Herpetic Neuralgia Treatment Market Outlook, by Treatment Type, Value (US$ Bn), 2018 - 2031
    • 7.1.1. Key Highlights
      • 7.1.1.1. Drugs
        • 7.1.1.1.1. Anticonvulsants
        • 7.1.1.1.2. Antidepressants
        • 7.1.1.1.3. Opioids
      • 7.1.1.2. Patches
        • 7.1.1.2.1. Lidocaine Patches
        • 7.1.1.2.2. Capsaicin Patches
      • 7.1.1.3. Steroid Injectable
  • 7.2. Latin America Post Herpetic Neuralgia Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 7.2.1. Key Highlights
      • 7.2.1.1. Institutional Sales
        • 7.2.1.1.1. Hospital Pharmacies
        • 7.2.1.1.2. Clinics
      • 7.2.1.2. Retail Sales
        • 7.2.1.2.1. Retail Pharmacies
        • 7.2.1.2.2. Drug Stores
        • 7.2.1.2.3. Mail Order Pharmacies
  • 7.3. Latin America Post Herpetic Neuralgia Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 7.3.1. Key Highlights
      • 7.3.1.1. Brazil Post Herpetic Neuralgia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
      • 7.3.1.2. Brazil Post Herpetic Neuralgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 7.3.1.3. Mexico Post Herpetic Neuralgia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
      • 7.3.1.4. Mexico Post Herpetic Neuralgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 7.3.1.5. Argentina Post Herpetic Neuralgia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
      • 7.3.1.6. Argentina Post Herpetic Neuralgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 7.3.1.7. Rest of Latin America Post Herpetic Neuralgia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
      • 7.3.1.8. Rest of Latin America Post Herpetic Neuralgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 7.3.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Post Herpetic Neuralgia Treatment Market Outlook, 2018 - 2031

  • 8.1. Middle East & Africa Post Herpetic Neuralgia Treatment Market Outlook, by Treatment Type, Value (US$ Bn), 2018 - 2031
    • 8.1.1. Key Highlights
      • 8.1.1.1. Drugs
        • 8.1.1.1.1. Anticonvulsants
        • 8.1.1.1.2. Antidepressants
        • 8.1.1.1.3. Opioids
      • 8.1.1.2. Patches
        • 8.1.1.2.1. Lidocaine Patches
        • 8.1.1.2.2. Capsaicin Patches
      • 8.1.1.3. Steroid Injectable
  • 8.2. Middle East & Africa Post Herpetic Neuralgia Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 8.2.1. Key Highlights
      • 8.2.1.1. Institutional Sales
        • 8.2.1.1.1. Hospital Pharmacies
        • 8.2.1.1.2. Clinics
      • 8.2.1.2. Retail Sales
        • 8.2.1.2.1. Retail Pharmacies
        • 8.2.1.2.2. Drug Stores
        • 8.2.1.2.3. Mail Order Pharmacies
  • 8.3. Middle East & Africa Post Herpetic Neuralgia Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 8.3.1. Key Highlights
      • 8.3.1.1. GCC Post Herpetic Neuralgia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
      • 8.3.1.2. GCC Post Herpetic Neuralgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 8.3.1.3. South Africa Post Herpetic Neuralgia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
      • 8.3.1.4. South Africa Post Herpetic Neuralgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 8.3.1.5. Egypt Post Herpetic Neuralgia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
      • 8.3.1.6. Egypt Post Herpetic Neuralgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 8.3.1.7. Nigeria Post Herpetic Neuralgia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
      • 8.3.1.8. Nigeria Post Herpetic Neuralgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 8.3.1.9. Nigeria Post Herpetic Neuralgia Treatment Market Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 8.3.1.10. Rest of Middle East & Africa Post Herpetic Neuralgia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
      • 8.3.1.11. Rest of Middle East & Africa Post Herpetic Neuralgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 8.3.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. Treatment Type vs Distribution Channel Heatmap
  • 9.2. Manufacturer vs Distribution Channel Heatmap
  • 9.3. Company Market Share Analysis, 2023
  • 9.4. Competitive Dashboard
  • 9.5. Company Profiles
    • 9.5.1. Pfizer Inc.
      • 9.5.1.1. Company Overview
      • 9.5.1.2. Treatment Type Portfolio
      • 9.5.1.3. Financial Overview
      • 9.5.1.4. Business Strategies and Development
    • 9.5.2. Teva Pharmaceutical Industries Ltd.
      • 9.5.2.1. Company Overview
      • 9.5.2.2. Treatment Type Portfolio
      • 9.5.2.3. Financial Overview
      • 9.5.2.4. Business Strategies and Development
    • 9.5.3. Mylan N.V.
      • 9.5.3.1. Company Overview
      • 9.5.3.2. Treatment Type Portfolio
      • 9.5.3.3. Financial Overview
      • 9.5.3.4. Business Strategies and Development
    • 9.5.4. Endo Pharmaceuticals Inc.
      • 9.5.4.1. Company Overview
      • 9.5.4.2. Treatment Type Portfolio
      • 9.5.4.3. Financial Overview
      • 9.5.4.4. Business Strategies and Development
    • 9.5.5. Daiichi Sankyo
      • 9.5.5.1. Company Overview
      • 9.5.5.2. Treatment Type Portfolio
      • 9.5.5.3. Financial Overview
      • 9.5.5.4. Business Strategies and Development
    • 9.5.6. Acorda Therapeutics
      • 9.5.6.1. Company Overview
      • 9.5.6.2. Treatment Type Portfolio
      • 9.5.6.3. Financial Overview
      • 9.5.6.4. Business Strategies and Development
    • 9.5.7. Purdue Pharma L.P
      • 9.5.7.1. Company Overview
      • 9.5.7.2. Treatment Type Portfolio
      • 9.5.7.3. Financial Overview
      • 9.5.7.4. Business Strategies and Development
    • 9.5.8. Teikoku Pharma USA, Inc.
      • 9.5.8.1. Company Overview
      • 9.5.8.2. Treatment Type Portfolio
      • 9.5.8.3. Financial Overview
      • 9.5.8.4. Business Strategies and Development
    • 9.5.9. Janssen Pharmaceuticals, Inc.
      • 9.5.9.1. Company Overview
      • 9.5.9.2. Treatment Type Portfolio
      • 9.5.9.3. Financial Overview
      • 9.5.9.4. Business Strategies and Development

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations